nach oben

Erschienen in:

01.03.2009 | Original Paper

Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma

verfasst von: C. Meazza, M. Casanova, E. Zaffignani, R. Luksch, M. Podda, F. Favini, S. Catania, V. Biassoni, C. Morosi, A. Ferrari

Erschienen in: Medical Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background This study investigates the efficacy and the feasibility of a chemotherapy regimen with topotecan plus vincristine and doxorubicin (TVD) given on an individually tailored basis to patients with refractory/recurrent rhabdomyosarcoma (RMS). Patients and methods Nine patients received TVD therapy at relapse, and six were assessable for response. Results All the six patients experienced objective response after two cycles of chemotherapy: one minor response, four partial response, and one complete response. Conclusions The value of our study is severely limited by the small number of cases, the single-institutional setting and the individually tailored treatment, but we nonetheless confirmed the feasibility and tolerability of topotecan-based chemotherapy in RMS.

Gurney JG, Young JL, Roffers SD. Soft tissue sarcomas. In: Gloecker LA, Smith MA, editors. SEER pediatric monograph cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. Bethesda, MD: National Cancer Institute; 1999. p. 111–24.

Crist W, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610–30.PubMed

Baker S, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 1988;6:308–14.

Stewart C, Zamboni W, Crom W, Houghton P. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs. 1996;14:37–47. doi:10.1007/BF00173681.PubMedCrossRef

National Cancer Institute. NCI common toxicity criteria, version 1. Investigator’s handbook: a manual of participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute. Bethesda, MD: U.S. Department of Health and Human Services, Public Heath Service, National Institute of Health; 1993.

Thompson J, Stewart C, Houghton P. Animal models for studying the action of topoisomerase-I target drugs. Biochim Biophys Acta. 1998;1400:301–19.PubMed

Houghton PJ, et al. Evaluation of 9-dimethyminomethyl-10hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992;31:229–39. doi:10.1007/BF00685553.PubMedCrossRef

Rewinky K, Verweij J. Review of Phase I clinical studies with topotecan. Semin Oncol. 1998;24:3–20.

Tubergen DG, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) of topotecan using a five-days course in children with refractory solid tumors: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 1996;18:352–61. doi:10.1097/00043426-199611000-00004.PubMedCrossRef

10.

Nitschke R, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Ped Hematol Oncol. 1998;20:315–8. doi:10.1097/00043426-199807000-00006.CrossRef

11.

Pappo AS, et al. Up-front window trial of topotecan in previously untreated children and adolescents with matastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 2001;19:213–9.PubMed

12.

Saylors RL, et al. Pediatric oncology group: cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors. A Pediatric Oncology Group Phase II Study. J Clin Oncol. 2001;19:3463–9.PubMed

13.

Walterhouse DO, et al. Efficacy of topotecan and cyclophosphamide given in Phase II window trial in children with newly diagnosed matastatic rhabdomyosarcoma: a Children’s Oncology Group Study. J Clin Oncol. 2004;22:1398–403. doi:10.1200/JCO.2004.05.184.PubMedCrossRef

14.

Lager JJ, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2006;24:3415–22. doi:10.1200/JCO.2005.01.9497.PubMedCrossRef

15.

Breitfeld PP. Analysis of the therapeutic first-line Phase II window trials in rhabdomyosarcoma. Educational Book, American Society of Clinical Oncology Annual Meeting, Chicago, 2007; p. 607–10.

16.

Arndt CA, et al. Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG Study. Proc Am Soc Clin Oncol. 2007;25(188) (abstract 9509).

17.

Garaventa A, et al. A phase II Study of topotecan with vincristine and doxorubicine in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488–94. doi:10.1002/cncr.11797.PubMedCrossRef

18.

Rowinsky EK, Kaufmann SH. Topotecan in combination chemiotheraphy. Semin Oncol. 1997;24:S20-11–S20-26.

19.

Kim R, et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992;50:760–6. doi:10.1002/ijc.2910500516.PubMedCrossRef

20.

Thompson J, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999;5:3617–31.PubMed

21.

Cheung MF, Chatterjee S, Berger NA. Schedule-depend cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994;6:269–79.

22.

Jonsson E, Fridborg H, Nygren P. Synergistic interactions of combination of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998;54:509–14. doi:10.1007/s002280050505.PubMedCrossRef

Titel: Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma
verfasst von: C. Meazza
M. Casanova
E. Zaffignani
R. Luksch
M. Podda
F. Favini
S. Catania
V. Biassoni
C. Morosi
A. Ferrari
Publikationsdatum: 01.03.2009
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 1/2009
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-008-9085-8

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma

Abstract

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature

Squamous cell carcinoma of the renal pelvis

Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan

Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients

Association of TGIFLX/Y mRNA expression with prostate cancer

Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie